News & Investors

Investor Relations

Corporate Profile

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit.

Stock Price

Jan 16, 2022 4:20 PM EST

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News
Jan 13, 2022
Forma Therapeutics Elects Esteemed Clinician and Industry Veteran Arturo Molina, M.D., to Board of Directors and R&D Committee
Jan 07, 2022
Forma Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
Dec 16, 2021
Forma Therapeutics’ Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid Leukemia
Upcoming Events
Jan 13, 2022
7:30 AM EST
40th Annual J.P. Morgan Healthcare Conference
Learn more
Dec 13, 2021
8:00 AM EST
Investor Briefing to Discuss Clinical Data Presentations at the ASH Annual Meeting
Learn more
Nov 18, 2021
8:00 AM GMT
Jefferies London Healthcare Conference
Learn more